The estimated prevalence of dementia in 2013 was that there are 815,827 people with dementia in the UK, of whom 773,502 were aged 65 years or over. This represents one in every 79 (1.3%) of the entire UK population, and 1 in every 14 of the population aged 65 years and over. It is estimated that there are now 42,325 people with early-onset dementia (under the age of 65 years) in the UK. It would be unthinkable not to screen, diagnose and treat people with cancer, yet dementia is still not universally recognised, socially understood or professionally managed through adequate care and support. Reasons vary for low diagnosis rates in the UK; some families are reluctant to come forward for an early diagnosis because of the perceived social stigma attached to dementia or for fear of what lies ahead or early symptoms of dementia can be overlooked by health and care professionals by attributing short term memory loss to old age, UTI’s, stress, bereavement or other medical conditions. The progressive nature of the condition and the significant funding gap may also contribute to healthcare professionals questioning the benefits of early diagnosis.
A new drug believed to cause a 20 per cent reduction in heart failure deaths could present a 'major advance' in treatment. The drug, LCZ696, helps improve blood flow in heart failure patients. Heart failure is a syndrome caused by the heart not working properly, which can make people vulnerable to serious complications. A new study compared LCZ696 with an existing heart failure drug called enalapril, which is also used to treat high blood pressure.
Breakthrough hope for MS treatment as scientists discover how to ‘switch off’ autoimmune diseases. Autoimmune disorders, such as multiple sclerosis (MS), occur when the body’s immune system attacks and destroys healthy body tissue by mistake. The “holy grail” of treatment is to make the immune system tolerant to the part of the body that it is attacking, while still allowing the immune system to work effectively.
A recent study published in the Journal of Alzheimer’s Disease revealed that lavado (cocoa in its least-processed state), could reduce the amount of beta amyloid, a protein occurring in the brains of those with Alzheimer’s disease.
A group of scientists from the Institute of Biomedical Research of Barcelona have made a discovery that could lead to a test able to diagnose Alzheimer’s disease 10 years before any symptoms manifest in the individual.
During the years of study and training leading to qualification, medical professionals quite rightly focus on medicine. Yet when building a career in private medicine, one needs to develop business skills and adopt a more entrepreneurial outlook.